Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 31;17(2):210.
doi: 10.3390/v17020210.

Novel Oronasal Drainage for Long COVID: Proposed Mechanisms-Case Report

Affiliations
Case Reports

Novel Oronasal Drainage for Long COVID: Proposed Mechanisms-Case Report

Claudia Lorenz et al. Viruses. .

Abstract

Long COVID, potentially emerging post COVID-19 infection, involves extreme health challenges. Based on current literature in the field, we propose a novel approach to Long COVID treatment based on epipharyngeal abrasive therapy targeting ostia of the oral and nasal mucosa, having been identified for the first time. The presented case report documents the application of innovative oronasal drainage (OND), a novel treatment integrating physiological, biochemical, and fluid mechanical components simultaneously. OND led to remarkable improvements and even remissions of various symptoms, along with enhanced hand blood circulation. While the case suggests potential efficacy in Long COVID therapy, acknowledging inherent limitations is essential and its impact needs further validation through clinical trials.

Keywords: Long COVID; case report; myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); nose; oral; oronasal drainage (OND); ostia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure A1
Figure A1
Proposed mechanism of Oronasal Drainage (OND) for Long COVID treatment. Cycle chart outlining the hypothesized treatment cycle for OND. The proposed mechanism involves OND sessions lasting less than 20 min, followed by phases of exhaustion, thirst, and initial regeneration. Subsequently, hunger and food intake lead to a brief convalescence, succeeded by extended regeneration and prolonged convalescence.
Figure 1
Figure 1
Proposed site of action of Oronasal Drainage (OND) for Long COVID treatment. (a) Schematic depiction of the human oral and nasal cavity, where the white arrow signifies the region for epipharyngeal abrasive therapy, and the red-black dots indicate ostia as the site of action for OND. (b) Schematic representation of the human oral cavity highlights numerous ostia near the tonsilla palatina, with hidden plicae unfolding through mechanical stimulation using cotton swabs. The illustration shows an enlargement of (a), highlighted with a blue dashed outline. (c) Schematic representation of the human oral cavity illustrates the arrangement of ostia within the oropharynx. Our hypothesis posits that the opening of obstructed ostia is facilitated by biochemical stimulation using 0.5% zinc chloride (ZnCl2) solution.
Figure 2
Figure 2
Oronasal Drainage (OND): Procedure for a Long COVID patient. (a) Elongated, thread-like salivary secretion observed (white arrow). (b) OND in the oral cavity targeting ostia on the right palatine gland. Adhesion between tongue secretions and the swab shown by the black arrow. (c) OND on the nasal mucosa, focusing on the epipharyngeal mucosa. Visible onset of herpes simplex virus 1 (HSV-1) reactivation on the lower lip on the fourth day of OND (black arrow).
Figure 3
Figure 3
Removed nasal mucosa secretion during Oronasal Drainage (OND). (a) Stringy, transparent mucus measuring several centimeters. (b) Patient expelled long, stringy, transparent secretions through snorting (white triangle). On the fourth day of OND, a few green nasal secretions were observed (black triangle). (c) Nasal-mouth secretions. No S proteins were detected; the content, especially within brackets, remains unclear.
Figure 4
Figure 4
Impact of Oronasal Drainage (OND) on Long COVID Symptom Severity. (a) Weighted symptom severity score before, during (red bar) and after OND. Black data points represent symptoms (0 to 100, left y-axis) with mean displayed. Blue data points represent exercise intolerance, identified as post-exertional malaise (PEM) (0.0 to 1.0, right y-axis) with mean displayed. (b) The data encompass the complete symptom score. A thick horizontal bar within the boxplot represents the mean of symptom (0 to 250) with error bars denoting the standard error of the mean. (c) Symptom severity for dyspnea. A thick horizontal bar within the boxplot represents the mean of symptom (0 to 8) with error bars denoting the standard error of the mean; (b,c) reflect data collected before (−3 days), during (1–5 days), immediately after (6–10 days), and during follow-up (>10 days; n = 35) OND sessions.
Figure 5
Figure 5
Impact of Oronasal Drainage (OND) on Long COVID skin. (a) The upper panel illustrates the patient’s hands before OND, while the lower panel shows the patient’s hands on the fourth day of OND. (b) The upper panel illustrates the patient’s tongue before OND, while the lower panel shows the patient’s tongue on the fifth day of OND.

Similar articles

  • Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, Hooft L, Emperador D, Domen J, Tans A, Janssens S, Wickramasinghe D, Lannoy V, Horn SRA, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Struyf T, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
  • Interventions for palliative symptom control in COVID-19 patients.
    Andreas M, Piechotta V, Skoetz N, Grummich K, Becker M, Joos L, Becker G, Meissner W, Boehlke C. Andreas M, et al. Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD015061. doi: 10.1002/14651858.CD015061. Cochrane Database Syst Rev. 2021. PMID: 34425019 Free PMC article.
  • SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. Kreuzberger N, et al. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. Cochrane Database Syst Rev. 2021. PMID: 34473343 Free PMC article.
  • Ivermectin for preventing and treating COVID-19.
    Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, Kranke P, Meybohm P, Skoetz N, Weibel S. Popp M, et al. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3. Cochrane Database Syst Rev. 2022. PMID: 35726131 Free PMC article.
  • Colchicine for the treatment of COVID-19.
    Mikolajewska A, Fischer AL, Piechotta V, Mueller A, Metzendorf MI, Becker M, Dorando E, Pacheco RL, Martimbianco ALC, Riera R, Skoetz N, Stegemann M. Mikolajewska A, et al. Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045. Cochrane Database Syst Rev. 2021. PMID: 34658014 Free PMC article.

References

    1. Ivanova N., Sotirova Y., Gavrailov G., Nikolova K., Andonova V. Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic. Pharmaceutics. 2022;14:530. doi: 10.3390/pharmaceutics14030530. - DOI - PMC - PubMed
    1. Bellocchio L., Dipalma G., Inchingolo A.M., Inchingolo A.D., Ferrante L., Del Vecchio G., Malcangi G., Palermo A., Qendro A., Inchingolo F. COVID-19 on Oral Health: A New Bilateral Connection for the Pandemic. Biomedicines. 2023;12:60. doi: 10.3390/biomedicines12010060. - DOI - PMC - PubMed
    1. O’Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762. - DOI - PMC - PubMed
    1. Bai F., Tomasoni D., Falcinella C., Barbanotti D., Castoldi R., Mule G., Augello M., Mondatore D., Allegrini M., Cona A., et al. Female gender is associated with long COVID syndrome: A prospective cohort study. Clin. Microbiol. Infect. 2022;28:611.e9–611.e16. doi: 10.1016/j.cmi.2021.11.002. - DOI - PMC - PubMed
    1. Bowe B., Xie Y., Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat. Med. 2023;29:2347–2357. doi: 10.1038/s41591-023-02521-2. - DOI - PMC - PubMed

Publication types

LinkOut - more resources